Product Code: ARZ220102
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Artificial Intelligence in Genomics Market Report
The artificial intelligence in genomics market to grow at a CAGR of 48.44% during the forecast period
Artificial intelligence in drug discovery can make its development speedier and less hazardous which in turn is making it easy for clinicians to understand complicated diseases at the genetic level. The emergence of new and favorable applications for disease diagnosis and monitoring is expected to further drive the AI in genomics market growth. Several genomic-focused companies have shown favorable returns.
KEY HIGHLIGHTS
- In 2017, liquid biopsy company GRAIL raised an unprecedented USD 914 million in its Series B round led by Smart Money VC ARCH Venture Partners and including Johnson & Johnson to continue product development and validation for its early-stage cancer detection blood test.
- Another company that is making a lot of noise in the data-driven medicine space is Sophia Genetics from Switzerland. It already works with a half-dozen UK hospitals to pool data and bring AI-driven insights to cancer diagnostics, claiming to already diagnose hundreds of patients a day.
The following factors are likely to contribute to the growth of artificial intelligence in genomics market-
- Rising Investment by Government & Private Players in Genomics
- Emergence of Local and Regional Start-ups
- Emergence of Local and Regional Start-ups
- Rising Adoption of Machine Learning in Personalized/Precision Medicine
- Rising Focus on Reducing the Turnaround Time in Drugs Discovery & Diagnostics
ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SEGMENTS
AI in Genomics market is segmented by-
- Delivery mode
- Application
- End-user
- Geography
ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SEGMENTATION
- The on-premises segment accounted for a share of more than 60% of the global artificial intelligence (AI) in the genomics market in 2021. This is primarily attributed to the broad range of advantages associated with the use of on-premises software, such as high security of data, low risk of data breaches, and full command over software upgrades & data storage.
- The closer combination of AI and gene sequencing will help in the development of the genome sequencing market. Companies such as Deep Genomics, use machine learning to support researchers interpret genetic variation.
Segmentation by Delivery Mode
Segmentation by Functionality
- Genome Sequencing
- Gene Editing
- Others
Segmentation by Application
- Translational Precision Medicine
- Clinical & Genomic Diagnostics
- Others
Segmentation by End User
- Pharma & Biotech Companies
- Public & Consumer Genomic Centers
- Others
GEOGRAPHICAL OUTLOOK
North America: North America accounted for more than half of the share in the global artificial intelligence in the genomics market in 2021. The AI in genomics market is likely to increase in North America owing to the growing adoption of AI in genome sequencing and rising awareness among the regional pharma and biotech companies. AI deep learning algorithms have also saved many lives in North America by reducing the diagnosis-treatment-recovery cycle for patients.
Europe: The increased awareness among European patients drives the application of personal genome sequencing testing, especially for reproductive health. Artificial Intelligence (AI) is widely helping in diagnostics and contributing to accessible, affordable, and good quality healthcare, which is consequently improving accuracy.
Segmentation by Geography
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- APAC
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
VENDOR LANDSCAPE
- The key players in Artificial Intelligence in Genomics market are Fabric Genomics, International Business Machines, Microsoft, and
- Vendors are increasingly focusing on launching innovative devices to penetrate and tap the huge growth potential prevailing in the market.
Key Vendors
- Fabric Genomics
- International Business Machines
- Microsoft
- NVIDIA
Other Prominent Vendors
- AI Therapeutics
- Ares Genetics
- BenevolentAI
- Deep Genomics
- Diploid
- DNAnexus
- Emedgene
- Empiric Logic
- Engine Biosciences
- FDNA
- Freenome Holdings
- Genuity Science
- Lifebit
- MolecularMatch
- Predictive Oncology
- SOPHiA GENETICS
- Verge Genomics
- WhiteLab Genomics
KEY QUESTIONS ANSWERED:
- 1. What is the forecasted value of global Artificial Intelligence in genomics market size in 2027?
- 2. What factors will drive Artificial Intelligence (AI) in genomics market?
- 3. Who are the key players in Artificial Intelligence in genomics market?
- 4. What is the post-pandemic scenario of the Artificial Intelligence in genomics market?
- 5. What are some new product launches that created a buzz in the market?
TABLE OF CONTENTS
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
- 4.1 Market Definition
- 4.1.1 Inclusions
- 4.1.2 Exclusions
- 4.1.3 Market Estimation Caveats
- 4.2 Base Year
- 4.3 Scope of The Study
- 4.3.1 Market Segmentation by Delivery Mode
- 4.3.2 Market Segmentation by Functionality
- 4.3.3 Market Segmentation by Application
- 4.3.4 Market Segmentation by End-User
- 4.3.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
- 5.1 Key Caveats
- 5.2 Currency Conversion
- 5.3 Market Derivation
6 Market at a Glance
7 Introduction
- 7.1 AI in Healthcare
- 7.2 AI in Genomics
8 Market Opportunities & Trends
- 8.1 Investments by Government & Private Players
- 8.2 Emergence of Local and Regional Start-Ups
- 8.3 Collaborations of Pharmaceutical and Software Companies
- 8.4 Rising Adoption of MI In Personalized/Precision Medicine
9 Market Growth Enablers
- 9.1 Rising Focus on Reducing Turnaround Time in Drug Discovery & Diagnostics
- 9.2 Growing Adoption of Ai-Based Solutions
- 9.3 Increased Biomedical and Genomic Datasets
10 Market Restraints
- 10.1 Lack of Skilled Workforce & Infrastructure
- 10.2 Ambiguous Regulatory Guidelines for Genomics Software
- 10.3 Poor Security & Storage of Large Volumes of Genome Sequencing Data
11 Market Landscape
- 11.1 Market Overview
- 11.2 Market Size & Forecast
- 11.2.1 Geographic Insights
- 11.2.2 Delivery Mode Insights
- 11.2.3 Functionality Insights
- 11.2.4 Application Insights
- 11.2.5 End-User Insights
- 11.3 Five Forces Analysis
- 11.3.1 Threat of New Entrants
- 11.3.2 Bargaining Power of Suppliers
- 11.3.3 Bargaining Power of Buyers
- 11.3.4 Threat of Substitutes
- 11.3.5 Competitive Rivalry
12 Delivery Mode
- 12.1 Market Snapshot & Growth Engine
- 12.2 Market Overview
- 12.3 On-Premises
- 12.3.1 Market Overview
- 12.3.2 Market Size & Forecast
- 12.3.3 Market by Geography
- 12.4 Cloud-Based
- 12.4.1 Market Overview
- 12.4.2 Market Size & Forecast
- 12.4.3 Market by Geography
13 Functionality
- 13.1 Market Snapshot & Growth Engine
- 13.2 Market Overview
- 13.3 Genome Sequencing
- 13.3.1 Market Overview
- 13.3.2 Market Size & Forecast
- 13.3.3 Market by Geography
- 13.4 Gene Editing
- 13.4.1 Market Overview
- 13.4.2 Market Size & Forecast
- 13.4.3 Market by Geography
- 13.5 Others
- 13.5.1 Market Overview
- 13.5.2 Market Size & Forecast
- 13.5.3 Market by Geography
14 Application
- 14.1 Market Snapshot & Growth Engine
- 14.2 Market Overview
- 14.3 Translational Precision Medicine
- 14.3.1 Market Overview
- 14.3.2 Market Size & Forecast
- 14.3.3 Market by Geography
- 14.4 Clinical & Genomic Diagnosis
- 14.4.1 Market Overview
- 14.4.2 Market Size & Forecast
- 14.4.3 Market by Geography
- 14.5 Other Applications
- 14.5.1 Market Overview
- 14.5.2 Market Size & Forecast
- 14.5.3 Market by Geography
15 End-User
- 15.1 Market Snapshot & Growth Engine
- 15.2 Market Overview
- 15.3 Pharma & Biotech Companies
- 15.3.1 Market Overview
- 15.3.2 Market Size & Forecast
- 15.3.3 Market by Geography
- 15.4 Public & Consumer Genomic Centers
- 15.4.1 Market Overview
- 15.4.2 Market Size & Forecast
- 15.4.3 Market by Geography
- 15.5 Others
- 15.5.1 Market Overview
- 15.5.2 Market Size & Forecast
- 15.5.3 Market by Geography
16 Geography
- 16.1 Market Snapshot & Growth Engine
- 16.2 Geographic Overview
17 North America
- 17.1 Market Overview
- 17.2 Market Size & Forecast
- 17.3 North America: Delivery Mode
- 17.3.1 Market Size & Forecast
- 17.4 North America: Functionality
- 17.4.1 Market Size & Forecast
- 17.5 North America: Application
- 17.5.1 Market Size & Forecast
- 17.6 North America: End-User
- 17.6.1 Market Size & Forecast
- 17.7 Key Countries
- 17.7.1 US: Market Size & Forecast
- 17.7.2 Canada: Market Size & Forecast
18 Europe
- 18.1 Market Overview
- 18.2 Market Size & Forecast
- 18.3 Europe: Delivery Mode
- 18.3.1 Market Size & Forecast
- 18.4 Europe: Functionality
- 18.4.1 Market Size & Forecast
- 18.5 Europe: Application
- 18.5.1 Market Size & Forecast
- 18.6 Europe: End-User
- 18.6.1 Market Size & Forecast
- 18.7 Key Countries
- 18.7.1 Germany: Market Size & Forecast
- 18.7.2 UK: Market Size & Forecast
- 18.7.3 France: Market Size & Forecast
- 18.7.4 Italy: Market Size & Forecast
- 18.7.5 Spain: Market Size & Forecast
19 APAC
- 19.1 Market Overview
- 19.2 Market Size & Forecast
- 19.3 APAC: Delivery Mode
- 19.3.1 Market Size & Forecast
- 19.4 APAC: Functionality
- 19.4.1 Market Size & Forecast
- 19.5 APAC: Application
- 19.5.1 Market Size & Forecast
- 19.6 APAC: End-User
- 19.6.1 Market Size & Forecast
- 19.7 Key Countries
- 19.7.1 Japan: Market Size & Forecast
- 19.7.2 China: Market Size & Forecast
- 19.7.3 India: Market Size & Forecast
- 19.7.4 Australia: Market Size & Forecast
- 19.7.5 South Korea: Market Size & Forecast
20 Latin America
- 20.1 Market Overview
- 20.2 Market Size & Forecast
- 20.3 Latin America: Delivery Mode
- 20.3.1 Market Size & Forecast
- 20.4 Latin America: Functionality
- 20.4.1 Market Size & Forecast
- 20.5 Latin America: Application
- 20.5.1 Market Size & Forecast
- 20.6 Latin America: End-User
- 20.6.1 Market Size & Forecast
- 20.7 Key Countries
- 20.7.1 Brazil: Market Size & Forecast
- 20.7.2 Mexico: Market Size & Forecast
21 Middle East & Africa
- 21.1 Market Overview
- 21.2 Market Size & Forecast
- 21.3 Middle East & Africa: Delivery Mode
- 21.3.1 Market Size & Forecast
- 21.4 Middle East & Africa: Functionality
- 21.4.1 Market Size & Forecast
- 21.5 Middle East & Africa: Application
- 21.5.1 Market Size & Forecast
- 21.6 Middle East & Africa: End-User
- 21.6.1 Market Size & Forecast
- 21.7 Key Countries
- 21.7.1 Turkey: Market Size & Forecast
- 21.7.2 Saudi Arabia: Market Size & Forecast
- 21.7.3 South Africa: Market Size & Forecast
22 Competitive Landscape
- 22.1 Competition Overview
23 Key Company Profiles
- 23.1 FABRIC GENOMICS
- 23.1.1 Business Overview
- 23.1.2 Product Offerings
- 23.1.3 Key Strategies
- 23.1.4 Key Strengths
- 23.1.5 Key Opportunities
- 23.2 INTERNATIONAL BUSINESS MACHINES
- 23.2.1 Business Overview
- 23.2.2 Product Offerings
- 23.2.3 Key Strategies
- 23.2.4 Key Strengths
- 23.2.5 Key Opportunities
- 23.3 MICROSOFT
- 23.3.1 Business Overview
- 23.3.2 Product Offerings
- 23.3.3 Key Strategies
- 23.3.4 Key Strengths
- 23.3.5 Key Opportunities
- 23.4 NVIDIA
- 23.4.1 Business Overview
- 23.4.2 Product Offerings
- 23.4.3 Key Strategies
- 23.4.4 Key Strengths
- 23.4.5 Key Opportunities
24 Other Prominent Vendors
- 24.1 AI THERAPEUTICS
- 24.1.1 Business Overview
- 24.1.2 Product Offerings
- 24.2 ARES GENETICS
- 24.2.1 Business Overview
- 24.2.2 Product Offerings
- 24.3 BENEVOLENTAI
- 24.3.1 Business Overview
- 24.3.2 Product Offerings
- 24.4 DEEP GENOMICS
- 24.4.1 Business Overview
- 24.4.1 Product Offerings
- 24.5 DIPLOID
- 24.5.1 Business Overview
- 24.5.2 Product Offerings
- 24.6 DNANEXUS
- 24.6.1 Business Overview
- 24.6.2 Product Offerings
- 24.7 EMEDGENE
- 24.7.1 Business Overview
- 24.7.2 Product Offerings
- 24.8 EMPIRIC LOGIC
- 24.8.1 Business Overview
- 24.8.2 Product Offerings
- 24.9 ENGINE BIOSCIENCES
- 24.9.1 Business Overview
- 24.9.2 Product Offerings
- 24.10 FDNA
- 24.10.1 Business Overview
- 24.10.2 Product Offerings
- 24.11 FREENOME HOLDINGS
- 24.11.1 Business Overview
- 24.11.2 Product Offerings
- 24.12 GENUITY SCIENCE
- 24.12.1 Business Overview
- 24.12.2 Product Offerings
- 24.13 LIFEBIT
- 24.13.1 Business Overview
- 24.13.2 Product Offerings
- 24.14 MOLECULARMATCH
- 24.14.1 Business Overview
- 24.14.2 Product Offerings
- 24.15 PREDICTIVE ONCOLOGY
- 24.15.1 Business Overview
- 24.15.2 Product Offerings
- 24.16 SOPHIA GENETICS
- 24.16.1 Business Overview
- 24.16.2 Product Offerings
- 24.17 VERGE GENOMICS
- 24.17.1 Business Overview
- 24.17.2 Product Offerings
- 24.18 WHITELAB GENOMICS
- 24.18.1 Business Overview
- 24.18.2 Product Offerings
25 Report Summary
- 25.1 Key Takeaways
- 25.2 Strategic Recommendations
26 Quantitative Summary
- 26.1 Geography
- 26.1.1 North America: Delivery Mode
- 26.1.2 North America: Functionality
- 26.1.3 North America: Application
- 26.1.4 North America: End-User
- 26.1.5 Europe: Delivery Mode
- 26.1.6 Europe: Functionality
- 26.1.7 Europe: Application
- 26.1.8 Europe: End-User
- 26.1.9 APAC: Delivery Mode
- 26.1.10 APAC: Functionality
- 26.1.11 APAC: Application
- 26.1.12 APAC: End-User
- 26.1.13 Latin America: Delivery Mode
- 26.1.14 Latin America: Functionality
- 26.1.15 Latin America: Application
- 26.1.16 Latin America: End-User
- 26.1.17 Middle East & Africa: Delivery Mode
- 26.1.18 Middle East & Africa: Functionality
- 26.1.19 Middle East & Africa: Application
- 26.1.20 Middle East & Africa: End-User
- 26.2 Delivery Mode
- 26.2.1 On-Premises
- 26.2.2 Cloud-Based
- 26.3 Functionality
- 26.3.1 Genome Sequencing
- 26.3.2 Gene Editing
- 26.3.3 Others
- 26.4 Application
- 26.4.1 Translational Precision Medicine
- 26.4.2 Clinical & Genomic Diagnostics
- 26.4.3 Other Applications
- 26.5 End-User
- 26.5.1 Pharma & Biotech Companies
- 26.5.2 Public & Consumer Genomic Centers
- 26.5.3 Others
27 Appendix